Englander Institute for Precision Medicine
Found 797 results
Author Title Type [ Year(Asc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2022
Kasi PMurtaza.  2022.  Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.. Oncologist. 27(5):336-337.
Galluzzi L, Kroemer G.  2022.  Calreticulin surface presentation can promote quality control of hematopoietic stem cells.. Trends Immunol. 43(12):950-952.
Sternberg CN, Shin N, Chernyshov K, Calabrò F, Cerbone L, Procopio G, Miheecheva N, Sagaradze G, Zaichikova A, Samarina N et al..  2022.  Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment.. Front Oncol. 12:1006017.
Manic G, Galluzzi L, Vitale I.  2022.  Catastrophic DNA replication in unscheduled tetraploid cells.. Trends Genet. 38(8):787-788.
Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, Cacciapuoti MTeresa, Mensah AAdjeiwaa, Sartori G, Munz N et al..  2022.  Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.. Haematologica. 107(5):1131-1143.
Kulm S, Kolin DA, Langhans MT, Kaidi AC, Elemento O, Bostrom MP, Shen TS.  2022.  Characterization of Genetic Risk of End-Stage Knee Osteoarthritis Treated with Total Knee Arthroplasty: A Genome-Wide Association Study.. J Bone Joint Surg Am. 104(20):1814-1820.
Tang F, Xu D, Wang S, Wong CKhuan, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K et al..  2022.  Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.. Science. 376(6596):eabe1505.
Chennamadhavuni A, Kasi PMurtaza.  2022.  Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge.. Front Oncol. 12:847299.
Jobanputra V, Wrzeszczynski KO, Buttner R, Caldas C, Cuppen E, Grimmond S, Haferlach T, Mullighan C, Schuh A, Elemento O.  2022.  Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.. Semin Cancer Biol. 84:23-31.
Rosenquist R, Cuppen E, Buettner R, Caldas C, Dreau H, Elemento O, Frederix G, Grimmond S, Haferlach T, Jobanputra V et al..  2022.  Clinical utility of whole-genome sequencing in precision oncology.. Semin Cancer Biol. 84:32-39.
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M et al..  2022.  Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.. JCI Insight. 7(4)
Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, Fedrizzi T, Beltran H, Robinson DR, Gopalan A et al..  2022.  Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.. J Pathol. 257(3):274-284.
Kadri S, Sboner A, Sigaras A, Roy S.  2022.  Containers in Bioinformatics: Applications, Practical Considerations, and Best Practices in Molecular Pathology.. J Mol Diagn. 24(5):442-454.
Marchi S, Morroni G, Pinton P, Galluzzi L.  2022.  Control of host mitochondria by bacterial pathogens.. Trends Microbiol. 30(5):452-465.
Álvarez-Abril B, Bloy N, Galassi C, Sato A, Jiménez-Cortegana C, Klapp V, Aretz A, Guilbaud E, Buqué A, Galluzzi L et al..  2022.  Cytofluorometric assessment of acute cell death responses driven by radiation therapy.. Methods Cell Biol. 172:17-36.
Jiménez-Cortegana C, Klapp V, Bloy N, Galassi C, Sato A, Yamazaki T, Buqué A, Galluzzi L, Petroni G.  2022.  Cytofluorometric assessment of cell cycle progression in irradiated cells.. Methods Cell Biol. 172:1-16.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, E Crawford D, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á et al..  2022.  Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.. N Engl J Med. 386(12):1132-1142.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Manarite J, Muslin D, Farrington T, Tombal B.  2022.  Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.. Future Oncol. 18(21):2585-2597.
Berchuck JE, Baca SC, McClure HM, Korthauer K, Tsai HK, Nuzzo PVitale, Kelleher KM, He M, Steinharter JA, Zacharia S et al..  2022.  Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.. Clin Cancer Res. 28(5):928-938.
Wittenbecher C, Cuadrat R, Johnston L, Eichelmann F, Jäger S, Kuxhaus O, Prada M, F M DGreco, Hicks AA, Hoffman P et al..  2022.  Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology.. Nat Commun. 13(1):936.
Zhao JL, Fizazi K, Saad F, Chi KN, Taplin M-E, Sternberg CN, Armstrong AJ, de Bono JS, Duggan WT, Scher HI.  2022.  The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.. Clin Cancer Res. 28(5):860-869.
Wilson BE, Armstrong AJ, de Bono J, Sternberg CN, Ryan CJ, Scher HI, Smith MR, Rathkopf D, Logothetis CJ, Chi KN et al..  2022.  Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.. Eur J Cancer. 170:296-304.
Meleshko D, Yang R, Marks P, Williams S, Hajirasouliha I.  2022.  Efficient detection and assembly of non-reference DNA sequences with synthetic long reads.. Nucleic Acids Res. 50(18):e108.
Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.
de Wit R, Powles T, Castellano D, Necchi A, Lee J-L, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN et al..  2022.  Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. Br J Clin Pharmacol. 88(7):3182-3192.